<DOC>
	<DOCNO>NCT01408927</DOCNO>
	<brief_summary>The primary objective prospective clinical registry determine prevalence level thienopyridine resistance see population undergo contemporary percutaneous coronary intervention ( PCI ) coronary artery bypass surgery ( CABG ) .</brief_summary>
	<brief_title>Prevalence Level Thienopyridine Resistance Seen Contemporary Percutaneous Coronary Intervention Coronary Artery Bypass Graft Population</brief_title>
	<detailed_description>This prospective cohort study 1000 patient present Washington Hospital Center percutaneous coronary intervention coronary artery bypass surgery . The aim prospective clinical registry determine prevalence level thienopyridine resistance see population present cardiac catheterization undergo percutaneous coronary intervention ( PCI ) coronary artery bypass surgery ( CABG ) . Thienopyridine resistance measure flow cytometry vasodilator-stimulated phosphoprotein ( VASP ) phosphorylation , and/or VerifyNow P2Y12 assay , and/or Chrono-Log Lumi-Aggregometer , and/or PlaCor PRT 7000 platelet reactivity assay . A secondary objective study correlate variety genetic polymorphism level platelet reactivity .</detailed_description>
	<mesh_term>Aspirin</mesh_term>
	<criteria>1 . Patient &gt; 18 year old . 2 . PCI group : Patient schedule undergo cardiac catheterization underwent percutaneous coronary intervention ( PCI ) , hospital stay . 3 . CABG group : Patient schedule undergo , underwent , coronary artery bypass surgery least one saphenous vein graft . 4 . Treated load dose clopidogrel prasugrel least 6 hour prior blood draw , maintenance dose clopidogrel prasugrel minimum 5 day . 5 . Genetic test subgroup : Patient undergone PCI ( ) , treat thienopyridine 4 . 1 . Known allergy aspirin , clopidogrel , prasugrel ; 2 . Use glycoprotein ( GP ) IIb/IIIa within 8 hour blood draw ; 3 . Patient know pregnant lactating ; 4 . Patient known history bleed diathesis currently active bleeding ; 5 . Platelet count &lt; 100,000/mm day blood draw ; 6 . Hematocrit &lt; 25 % day blood draw ; 7 . On warfarin therapy time blood draw ; 8 . Known blood transfusion within precede 10 day blood draw ; 9 . Patient receive NSAID ( include ASA ) within precede 24 hour blood draw ; 10 . Any significant medical condition investigator 's opinion may interfere patient 's optimal participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Thienopyridine resistance</keyword>
	<keyword>Aspirin resistance</keyword>
	<keyword>Platelet reactivity</keyword>
</DOC>